RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Clinical trials for RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR trials appear
Sign up with your email to follow new studies for RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: trial targets a key genetic driver
Disease control OngoingThis study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted drug trial offers hope for kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for kids with tough cancers: treatment guided by tumor genetics
Disease control OngoingThis study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New hope for kids with tough cancers: drug targets genetic flaw
Disease control OngoingThis study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…
Matched conditions: RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC